Piperacillin-Tazobactam-Induced Immune Thrombocytopenia: A Case Report

Shangwe Kiliaki1

  • 1Department of Medicine, Division of Hospital Internal Medicine, 4352Mayo Clinic, Rochester, MN, USA.

Journal of Pharmacy Practice
|September 24, 2021
PubMed

Insights

Drug-induced immune thrombocytopenia (DITP) occurs when drugs trigger antibodies that destroy platelets. Promptly stopping the offending drug is crucial for recovery and preventing severe complications.

Area of Science:

  • Hematology
  • Immunology
  • Pharmacology

Background:

  • Drug-induced immune thrombocytopenia (DITP) is a serious condition characterized by accelerated platelet destruction.
  • It results from drug-dependent, platelet-reactive antibodies, with heparin-induced thrombocytopenia being the most common form.
  • Antibiotics like ceftriaxone, trimethoprim-sulfamethoxazole, vancomycin, and penicillin are frequently implicated in DITP.

Observation:

  • Thrombocytopenia in DITP can be severe, with platelet nadirs below 20 × 10^9/L.
  • Onset typically occurs 1-2 weeks after exposure to the causative drug.
  • A patient case illustrates DITP following piperacillin-tazobactam initiation for cellulitis in a diabetic foot ulcer.

Findings:

  • Diagnosis involves excluding other causes of thrombocytopenia; laboratory testing for drug-dependent antiplatelet antibodies can be supportive but is not mandatory.
  • Platelet counts usually improve within 1-2 days of drug discontinuation and normalize within a week.
  • Identifying and discontinuing the implicated medication is the cornerstone of management.

Implications:

  • DITP, though rare, can be fatal, underscoring the importance of timely diagnosis and intervention.
  • Early recognition and withdrawal of the offending agent are critical for preventing serious complications.
  • This case highlights the potential for piperacillin-tazobactam to induce DITP, emphasizing vigilance in patients with risk factors.